» Articles » PMID: 24909095

Risk of Second Primary Lung Cancer in Women After Radiotherapy for Breast Cancer

Overview
Journal Radiother Oncol
Specialties Oncology
Radiology
Date 2014 Jun 10
PMID 24909095
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Several epidemiological studies have reported increased risks of second lung cancers after breast cancer irradiation. In this study we assessed the effects of the delivered radiation dose to the lung and the risk of second primary lung cancer.

Methods: We conducted a nested case-control study of second lung cancer in a population based cohort of 23,627 early breast cancer patients treated with post-operative radiotherapy from 1982 to 2007. The cohort included 151 cases diagnosed with second primary lung cancer and 443 controls. Individual dose-reconstructions were performed and the delivered dose to the center of the second lung tumor and the comparable location for the controls were estimated, based on the patient specific radiotherapy charts.

Results: The median age at breast cancer diagnosis was 54 years (range 34-74). The median time from breast cancer treatment to second lung cancer diagnosis was 12 years (range 1-26 years). 91% of the cases were categorized as ever smokers vs. 40% among the controls. For patients diagnosed with a second primary lung cancer five or more years after breast cancer treatment the rate of lung cancer increased linearly with 8.5% per Gray (95% confidence interval=3.1-23.3%; p<0.001). This rate was enhanced for ever smokers with an excess rate of 17.3% per Gray (95% CI=4.5-54%; p<0.005).

Conclusions: Second lung cancer after radiotherapy for early breast cancer is associated with the delivered dose to the lung. Although the absolute risk is relative low, the growing number of long-time survivors after breast cancer treatment highlights the need for advances in normal tissue sparing radiation techniques.

Citing Articles

Development of a Second Primary Lung Cancer Following a Primary Breast Cancer: A Case Series.

Sua L, Osorio A, Zuniga-Restrepo V, Ibarra C, Quintero N, Fernandez-Trujillo L J Investig Med High Impact Case Rep. 2024; 12:23247096241272013.

PMID: 39390783 PMC: 11468341. DOI: 10.1177/23247096241272013.


Proton therapy for breast cancer: Reducing toxicity.

Qiao K, Wei Y, Tao C, Zhu J, Yuan S Thorac Cancer. 2024; 15(30):2156-2165.

PMID: 39275876 PMC: 11496198. DOI: 10.1111/1759-7714.15451.


Incidental detection of ground glass nodules and primary lung cancer in patients with breast cancer: prevalence and long-term follow-up on chest computed tomography.

Ryu H, Lee H, Kim J, Ryu J, Lim Y J Thorac Dis. 2024; 16(3):1804-1814.

PMID: 38617779 PMC: 11009589. DOI: 10.21037/jtd-23-1605.


Spot-scanning proton therapy for early breast cancer in free breathing versus deep inspiration breath-hold.

Stick L, Nielsen L, Trinh C, Bahij I, Jensen M, Jensenius Skovhus Kronborg C Acta Oncol. 2024; 63:56-61.

PMID: 38404218 PMC: 11332550. DOI: 10.2340/1651-226X.2024.28591.


Hybrid VMAT-3DCRT as breast cancer treatment improvement tool.

Voyant C, Pinpin M, Leschi D, Prapant S, Savigny F, Acquaviva M Sci Rep. 2024; 13(1):23110.

PMID: 38172237 PMC: 10764879. DOI: 10.1038/s41598-023-50538-x.